[Federal Register Volume 84, Number 162 (Wednesday, August 21, 2019)]
[Notices]
[Page 43608]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-18026]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-2396]


Psychopharmacologic Drugs Advisory Committee; Cancellation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The meeting of the Psychopharmacologic Drugs Advisory 
Committee scheduled for July 31, 2019, has been canceled. This meeting 
was announced in the Federal Register of June 14, 2019. This meeting 
has been canceled because of new information regarding the application. 
The Agency intends to continue evaluating the application and, as 
needed, will announce future meeting dates in the Federal Register.

FOR FURTHER INFORMATION CONTACT: Jay Fajiculay, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, Fax: 301-847-8533, email: PDAC@fda.hhs.gov, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), and follow the prompts to the desired center or 
product area. Please call the Information Line for up-to-date 
information on this meeting, which was announced in the Federal 
Register of June 14, 2019 (84 FR 27783).

    Dated: August 16, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-18026 Filed 8-20-19; 8:45 am]
BILLING CODE 4164-01-P


